Sequence and structure requirements for specific recognition of HIV-1 TAR and DIS RNA by the HIV-1 Vif protein

RNA Biology

Volumn 9, Issue 7, 2012, Pages 966-977

  Freisz, Séverine ^a   Mezher, Joelle ^a   Hafirassou, Lamine ^a   Wolff, Philippe ^a   Nominé, Yves ^a   Romier, Christophe ^a   Dumas, Philippe ^a   Ennifar, Eric ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Biophysics; HIV; Microcalorimetry; RNA protein interactions

Indexed keywords

GENOMIC RNA; GENOMIC RNA TAR; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS RNA;

AMINO ACID SEQUENCE; ARTICLE; BIOPHYSICS; DIMERIZATION; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOTHERMAL TITRATION CALORIMETRY; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN RNA BINDING; PROTEIN STRUCTURE; TRANSCRIPTION INITIATION SITE;

EID: 84865294380     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.20483     Document Type: Article

References (85)

1. Fisher AG, Ensoli B, Ivanoff L, Chamberlain M, Petteway S, Ratner L, et al. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 1987; 237:888-93; PMID:3497453; http://dx.doi.org/10.1126/science. 3497453.
2. + T lymphocytes. J Virol 1992; 66:6489-95; PMID:1357189.
3. Gallo R, Wong-Staal F, Montagnier L, Haseltine WA, Yoshida M. HIV/HTLV gene nomenclature. Nature 1988; 333:504; PMID:2836736; http://dx.doi.org/10. 1038/333504a0.
4. Sodroski J, Goh WC, Rosen C, Tartar A, Portetelle D, Burny A, et al. Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science 1986; 231:1549-53; PMID:3006244; http://dx.doi.org/10.1126/science. 3006244.
5. Strebel K, Daugherty D, Clouse K, Cohen D, Folks T, Martin MA. The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 1987; 328:728-30; PMID:2441266; http://dx.doi.org/10.1038/328728a0.
6. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, et al. DNA deamination mediates innate immunity to retroviral infection. Cell 2003; 113:803-9; PMID:12809610; http://dx.doi.org/10.1016/S0092-8674(03)00423-9.
7. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003; 424:94-8; PMID:12808465; http://dx.doi.org/10.1038/nature01707.
8. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424:99-103; PMID:12808466; http://dx.doi.org/10.1038/nature01709.
9. Bishop KN, Holmes RK, Malim MH. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 2006; 80:8450-8; PMID:16912295; http://dx.doi.org/10.1128/JVI.00839-06.
10. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 2008; 4:1000231; PMID:19057663; http://dx.doi.org/10.1371/journal.ppat.1000231.
11. Holmes RK, Malim MH, Bishop KN. APOBEC-mediated viral restriction: not simply editing? Trends Biochem Sci 2007; 32:118-28; PMID:17303427; http://dx.doi.org/10.1016/j.tibs.2007.01.004.
12. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 2004; 14:1392-6; PMID:15296758; http://dx.doi.org/10.1016/j.cub.2004.06.057.
13. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418:646-50; PMID:12167863; http://dx.doi.org/10.1038/nature00939.
14. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J 2004; 23:2451-8; PMID:15152192; http://dx.doi.org/10.1038/sj. emboj.7600246.
15. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 2004; 78:6073-6; PMID:15141007; http://dx.doi.org/10.1128/ JVI.78.11.6073-6.2004.
16. Doehle BP, Schäfer A, Cullen BR. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 2005; 339:281-8; PMID:15993456; http://dx.doi.org/10.1016/j.virol.2005.06.005.
17. Dang Y, Wang X, Esselman WJ, Zheng YH. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol 2006; 80:10522-33; PMID:16920826; http://dx.doi.org/10.1128/JVI.01123-06.
18. Dang Y, Siew LM, Wang X, Han Y, Lampen R, Zheng YH. Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J Biol Chem 2008; 283:11606-14; PMID:18299330; http://dx.doi.org/10.1074/jbc.M707586200.
19. Stenglein MD, Harris RS. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Biol Chem 2006; 281:16837-41; PMID:16648136; http://dx.doi.org/10.1074/jbc.M602367200.
20. OhAinle M, Kerns JA, Malik HS, Emerman M. Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J Virol 2006; 80:3853-62; PMID:16571802; http://dx.doi.org/10.1128/JVI.80.8.3853- 62.2006.
21. Chiu YL, Greene WC. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol 2008; 26:317-53; PMID:18304004; http://dx.doi.org/10.1146/annurev. immunol.26.021607.090350.
22. Henriet S, Mercenne G, Bernacchi S, Paillart JC, Marquet R. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev 2009; 73:211-32; PMID:19487726; http://dx.doi.org/10. 1128/MMBR.00040-08.
23. Wissing S, Galloway NL, Greene WC. HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med 2010; 31:383-97; PMID:20538015; http://dx.doi.org/10.1016/j. mam.2010.06.001.
24. Conticello SG, Harris RS, Neuberger MS. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 2003; 13:2009-13; PMID:14614829; http://dx.doi.org/10.1016/j.cub.2003.10.034.
25. Marin M, Rose KM, Kozak SL, Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003; 9:1398-403; PMID:14528301; http://dx.doi.org/10.1038/nm946.
26. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 2004; 279:7792-8; PMID:14672928; http://dx.doi.org/10.1074/jbc.M313093200.
27. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003; 9:1404-7; PMID:14528300; http://dx.doi.org/10.1038/nm945.
28. Stopak K, de Noronha C, Yonemoto W, Greene WC. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 2003; 12:591-601; PMID:14527406; http://dx.doi.org/10.1016/S1097-2765(03)00353-8.
29. Hultquist JF, Binka M, LaRue RS, Simon V, Harris RS. Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors. J Virol 2012; 86:2874-7; PMID:22205746; http://dx.doi.org/10.1128/JVI.06950-11.
30. Jäger S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, et al. Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. Nature 2012; 481:371-5; PMID:22190037.
31. Zhang W, Du J, Evans SL, Yu Y, Yu XF. T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. Nature 2012; 481:376-9; PMID:22190036.
32. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol 2003; 77:11398-407; PMID:14557625; http://dx.doi.org/10. 1128/JVI.77.21.11398-407.2003.
33. Mercenne G, Bernacchi S, Richer D, Bec G, Henriet S, Paillart JC, et al. HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Res 2010; 38:633-46; PMID:19910370; http://dx.doi.org/10.1093/nar/gkp1009.
34. Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, Bollman B, et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003; 114:21-31; PMID:12859895; http://dx.doi.org/10.1016/S0092-8674(03) 00515-4.
35. Opi S, Kao S, Goila-Gaur R, Khan MA, Miyagi E, Takeuchi H, et al. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J Virol 2007; 81:8236-46; PMID:17522211; http://dx.doi.org/10.1128/JVI.02694-06.
36. Dettenhofer M, Cen S, Carlson BA, Kleiman L, Yu XF. Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J Virol 2000; 74:8938-45; PMID:10982337; http://dx.doi.org/10. 1128/JVI.74.19.8938-45.2000.
37. Henriet S, Richer D, Bernacchi S, Decroly E, Vigne R, Ehresmann B, et al. Cooperative and specific binding of Vif to the 5' region of HIV-1 genomic RNA. J Mol Biol 2005; 354:55-72; PMID:16236319; http://dx.doi.org/10.1016/j.jmb.2005. 09.025.
38. Khan MA, Akari H, Kao S, Aberham C, Davis D, Buckler-White A, et al. Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function. J Virol 2002; 76:9112-23; PMID:12186895; http://dx.doi.org/10.1128/JVI.76.18.9112-23.2002.
39. Zhang H, Pomerantz RJ, Dornadula G, Sun Y. Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol 2000; 74:8252-61; PMID:10954522; http://dx.doi.org/10.1128/JVI.74.18.8252-61.2000.
40. Barraud P, Paillart JC, Marquet R, Tisné C. Advances in the structural understanding of Vif proteins. Curr HIV Res 2008; 6:91-9; PMID:18336256; http://dx.doi.org/10.2174/157016208783885056.
41. Bernacchi S, Henriet S, Dumas P, Paillart JC, Marquet R. RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study. J Biol Chem 2007; 282:26361-8; PMID:17609216; http://dx.doi.org/10.1074/jbc.M703122200.
42. Bernacchi S, Mercenne G, Tournaire C, Marquet R, Paillart JC. Importance of the proline-rich multimerization domain on the oligomerization and nucleic acid binding properties of HIV-1 Vif. Nucleic Acids Res 2011; 39:2404-15; PMID:21076154; http://dx.doi.org/10.1093/nar/gkq979.
43. Auclair JR, Green KM, Shandilya S, Evans JE, Somasundaran M, Schiffer CA. Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins 2007; 69:270-84; PMID:17598142; http://dx.doi.org/10.1002/prot.21471.
44. Yang S, Sun Y, Zhang H. The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J Biol Chem 2001; 276:4889-93; PMID:11071884; http://dx.doi.org/10.1074/ jbc.M004895200.
45. Donahue JP, Vetter ML, Mukhtar NA, D'Aquila RT. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. Virology 2008; 377:49-53; PMID:18499212; http://dx.doi.org/10.1016/j.virol.2008.04.017.
46. Miller JH, Presnyak V, Smith HC. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology 2007; 4:81; PMID:18036235; http://dx.doi.org/10.1186/1742-4690-4- 81.
47. Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, et al. Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J Biol Chem 2003; 278:6596-602; PMID:12480936; http://dx.doi.org/10.1074/jbc.M210164200.
48. Bergeron JR, Huthoff H, Veselkov DA, Beavil RL, Simpson PJ, Matthews SJ, et al. The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathog 2010; 6:1000925; PMID:20532212; http://dx.doi.org/10.1371/journal.ppat.1000925.
49. Gallerano D, Devanaboyina SC, Swoboda I, Linhart B, Mittermann I, Keller W, et al. Biophysical characterization of recombinant HIV-1 subtype C virus infectivity factor. Amino Acids 2011; 40:981-9; PMID:20809132; http://dx.doi.org/10.1007/s00726-010-0725-x.
50. Yang X, Goncalves J, Gabuzda D. Phosphorylation of Vif and its role in HIV-1 replication. J Biol Chem 1996; 271:10121-9; PMID:8626571; http://dx.doi.org/10.1074/jbc.271.17.10121.
51. Marcsisin SR, Engen JR. Molecular insight into the conformational dynamics of the Elongin BC complex and its interaction with HIV-1 Vif. J Mol Biol 2010; 402:892-904; PMID:20728451; http://dx.doi.org/10.1016/j.jmb.2010.08. 026.
52. Marcsisin SR, Narute PS, Emert-Sedlak LA, Kloczewiak M, Smithgall TE, Engen JR. On the solution conformation and dynamics of the HIV-1 viral infectivity factor. J Mol Biol 2011; 410:1008-22; PMID:21763503; http://dx.doi.org/10.1016/j.jmb.2011.04.053.
53. Paul I, Cui J, Maynard EL. Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc Natl Acad Sci USA 2006; 103:18475-80; PMID:17132731; http://dx.doi.org/10.1073/pnas.0604150103.
54. Feig AL. Studying RNA-RNA and RNA-protein interactions by isothermal titration calorimetry. Methods Enzymol 2009; 468:409-22; PMID:20946780; http://dx.doi.org/10.1016/S0076-6879(09)68019-8.
55. Salim NN, Feig AL. Isothermal titration calorimetry of RNA. Methods 2009; 47:198-205; PMID:18835447; http://dx.doi.org/10.1016/j.ymeth.2008.09.003.
56. Velázquez Campoy A, Freire E. ITC in the post-genomic era...? Priceless. Biophys Chem 2005; 115:115-24; PMID:15752592; http://dx.doi.org/10. 1016/j.bpc.2004.12.015.
57. Ennifar E, Paillart JC, Bernacchi S, Walter P, Pale P, Decout JL, et al. A structure-based approach for targeting the HIV-1 genomic RNA dimerization initiation site. Biochimie 2007; 89:1195-203; PMID:17434658; http://dx.doi.org/10.1016/j.biochi.2007.03.003.
58. Paillart JC, Shehu-Xhilaga M, Marquet R, Mak J. Dimerization of retroviral RNA genomes: an inseparable pair. Nat Rev Microbiol 2004; 2:461-72; PMID:15152202; http://dx.doi.org/10.1038/nrmicro903.
59. Shen N, Jetté L, Wainberg MA, Laughrea M. Role of stem B, loop B and nucleotides next to the primer binding site and the kissing-loop domain in human immunodeficiency virus type 1 replication and genomic-RNA dimerization. J Virol 2001; 75:10543-9; PMID:11581429; http://dx.doi.org/10.1128/JVI.75.21. 10543-9.2001.
60. Hagan NA, Fabris D. Dissecting the protein-RNA and RNA-RNA interactions in the nucleocapsid-mediated dimerization and isomerization of HIV-1 stemloop 1. J Mol Biol 2007; 365:396-410; PMID:17070549; http://dx.doi.org/10.1016/j.jmb. 2006.09.081.
61. Ennifar E, Dumas P. Polymorphism of bulged-out residues in HIV-1 RNA DIS kissing complex and structure comparison with solution studies. J Mol Biol 2006; 356:771-82; PMID:16403527; http://dx.doi.org/10.1016/j.jmb.2005.12.022.
62. Ennifar E, Walter P, Ehresmann B, Ehresmann C, Dumas P. Crystal structures of coaxially stacked kissing complexes of the HIV-1 RNA dimerization initiation site. Nat Struct Biol 2001; 8:1064-8; PMID:11702070; http://dx.doi.org/10.1038/nsb727.
63. Ennifar E, Walter P, Dumas P. Cation-dependent cleavage of the duplex form of the subtype-B HIV-1 RNA dimerization initiation site. Nucleic Acids Res 2010; 38:5807-16; PMID:20460458; http://dx.doi.org/10.1093/nar/gkq344.
64. Ennifar E, Yusupov M, Walter P, Marquet R, Ehresmann B, Ehresmann C, et al. The crystal structure of the dimerization initiation site of genomic HIV-1 RNA reveals an extended duplex with two adenine bulges. Structure 1999; 7:1439-49; PMID:10574792; http://dx.doi.org/10.1016/S0969-2126(00)80033-7.
65. Muriaux D, De Rocquigny H, Roques BP, Paoletti J. NCp7 activates HIV-1Lai RNA dimerization by converting a transient loop-loop complex into a stable dimer. J Biol Chem 1996; 271:33686-92; PMID:8969239; http://dx.doi.org/10.1074/ jbc.271.52.33686.
66. Takahashi KI, Baba S, Chattopadhyay P, Koyanagi Y, Yamamoto N, Takaku H, et al. Structural requirement for the two-step dimerization of human immunodeficiency virus type 1 genome. RNA 2000; 6:96-102; PMID:10668802; http://dx.doi.org/10.1017/S1355838200991635.
67. Roy S, Delling U, Chen CH, Rosen CA, Sonenberg N. A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. Genes Dev 1990; 4:1365-73; PMID:2227414; http://dx.doi.org/10.1101/gad.4.8.1365.
68. Weeks KM, Ampe C, Schultz SC, Steitz TA, Crothers DM. Fragments of the HIV-1 Tat protein specifically bind TAR RNA. Science 1990; 249:1281-5; PMID:2205002; http://dx.doi.org/10.1126/science.2205002.
69. Karn J. Tackling Tat. J Mol Biol 1999; 293:235-54; PMID:10550206; http://dx.doi.org/10.1006/jmbi.1999.3060.
70. Davis B, Afshar M, Varani G, Murchie AI, Karn J, Lentzen G, et al. Rational design of inhibitors of HIV-1 TAR RNA through the stabilisation of electrostatic "hot spots". J Mol Biol 2004; 336:343-56; PMID:14757049; http://dx.doi.org/10.1016/j.jmb.2003.12.046.
71. Hamy F, Felder ER, Heizmann G, Lazdins J, Aboulela F, Varani G, et al. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci USA 1997; 94:3548-53; PMID:9108013; http://dx.doi.org/10.1073/pnas.94.8.3548.
72. Lalonde MS, Lobritz MA, Ratcliff A, Chamanian M, Athanassiou Z, Tyagi M, et al. Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. PLoS Pathog 2011; 7:1002038; PMID:21625572; http://dx.doi.org/10.1371/journal. ppat.1002038.
73. Mei HY, Mack DP, Galan AA, Halim NS, Heldsinger A, Loo JA, et al. Discovery of selective, small-molecule inhibitors of RNA complexes-I. The Tat protein/TAR RNA complexes required for HIV-1 transcription. Bioorg Med Chem 1997; 5:1173-84; PMID:9222511; http://dx.doi.org/10.1016/S0968-0896(97)00064-3.
74. Khan MA, Kao S, Miyagi E, Takeuchi H, Goila-Gaur R, Opi S, et al. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J Virol 2005; 79:5870-4; PMID:15827203; http://dx.doi.org/10.1128/JVI.79.9.5870-4.2005.
75. Bernacchi S, Freisz S, Maechling C, Spiess B, Marquet R, Dumas P, et al. Aminoglycoside binding to the HIV-1 RNA dimerization initiation site: thermodynamics and effect on the kissing-loop to duplex conversion. Nucleic Acids Res 2007; 35:7128-39; PMID:17942426; http://dx.doi.org/10.1093/nar/gkm856.
76. Ennifar E, Paillart JC, Bodlenner A, Walter P, Weibel JM, Aubertin AM, et al. Targeting the dimerization initiation site of HIV-1 RNA with aminoglycosides: from crystal to cell. Nucleic Acids Res 2006; 34:2328-39; PMID:16679451; http://dx.doi.org/10.1093/nar/gkl317.
77. Ennifar E, Paillart JC, Marquet R, Ehresmann B, Ehresmann C, Dumas P, et al. HIV-1 RNA dimerization initiation site is structurally similar to the ribosomal A site and binds aminoglycoside antibiotics. J Biol Chem 2003; 278:2723-30; PMID:12435744; http://dx.doi.org/10.1074/jbc.M205726200.
78. Freisz S, Lang K, Micura R, Dumas P, Ennifar E. Binding of aminoglycoside antibiotics to the duplex form of the HIV-1 genomic RNA dimerization initiation site. Angew Chem Int Ed Engl 2008; 47:4110-3; PMID:18435520; http://dx.doi.org/10.1002/anie.200800726.
79. Nguyen KL, llano M, Akari H, Miyagi E, Poeschla EM, Strebel K, et al. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 2004; 319:163-75; PMID:15015498; http://dx.doi.org/10.1016/j.virol.2003.11.021.
80. Romier C, Ben Jelloul M, Albeck S, Buchwald G, Busso D, Celie PH, et al. Co-expression of protein complexes in prokaryotic and eukaryotic hosts: experimental procedures, database tracking and case studies. Acta Crystallogr D Biol Crystallogr 2006; 62:1232-42; PMID:17001100; http://dx.doi.org/10.1107/ S0907444906031003.
81. Whitmore L, Wallace BA. Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databases. Biopolymers 2008; 89:392-400; PMID:17896349; http://dx.doi.org/10.1002/bip.20853.
82. Ennifar E, Walter P, Dumas P. A crystallographic study of the binding of 13 metal ions to two related RNA duplexes. Nucleic Acids Res 2003; 31:2671-82; PMID:12736317; http://dx.doi.org/10.1093/nar/gkg350.
83. Bernacchi S, Ennifar E, Tóth K, Walter P, Langowski J, Dumas P. Mechanism of hairpin-duplex conversion for the HIV-1 dimerization initiation site. J Biol Chem 2005; 280:40112-21; PMID:16169845; http://dx.doi.org/10.1074/ jbc.M503230200.
84. Ennifar E, Bernacchi S, Wolff P, Dumas P. Influence of C-5 halogenation of uridines on hairpin versus duplex RNA folding. RNA 2007; 13:1445-52; PMID:17630326; http://dx.doi.org/10.1261/rna.408507.
85. Burnouf D, Ennifar E, Guedich S, Puffer B, Hoffmann G, Bec G, et al. kinITC: a new method for obtaining joint thermodynamic and kinetic data by isothermal titration calorimetry. J Am Chem Soc 2012; 134:559-65; PMID:22126339; http://dx.doi.org/10.1021/ja209057d.